KR20040036272A - A composition for promoting growth or secretion of growth hormone comprising an extract of artemisia capillaris thunberg. and functional cereals coated by same - Google Patents
A composition for promoting growth or secretion of growth hormone comprising an extract of artemisia capillaris thunberg. and functional cereals coated by same Download PDFInfo
- Publication number
- KR20040036272A KR20040036272A KR1020020065230A KR20020065230A KR20040036272A KR 20040036272 A KR20040036272 A KR 20040036272A KR 1020020065230 A KR1020020065230 A KR 1020020065230A KR 20020065230 A KR20020065230 A KR 20020065230A KR 20040036272 A KR20040036272 A KR 20040036272A
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- growth
- extract
- weight
- coated
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 61
- 239000000122 growth hormone Substances 0.000 title claims abstract description 44
- 108010051696 Growth Hormone Proteins 0.000 title claims abstract description 42
- 102000018997 Growth Hormone Human genes 0.000 title claims abstract description 42
- 239000000284 extract Substances 0.000 title claims abstract description 38
- 235000013339 cereals Nutrition 0.000 title claims abstract description 35
- 230000012010 growth Effects 0.000 title claims abstract description 35
- 230000028327 secretion Effects 0.000 title claims abstract description 27
- 230000001737 promoting effect Effects 0.000 title claims abstract description 17
- 235000008658 Artemisia capillaris Nutrition 0.000 title claims abstract description 5
- 241000092668 Artemisia capillaris Species 0.000 title claims abstract description 5
- 240000007594 Oryza sativa Species 0.000 claims abstract description 22
- 235000007164 Oryza sativa Nutrition 0.000 claims abstract description 22
- 235000009566 rice Nutrition 0.000 claims abstract description 22
- 229920002472 Starch Polymers 0.000 claims abstract description 13
- 239000008107 starch Substances 0.000 claims abstract description 13
- 235000019698 starch Nutrition 0.000 claims abstract description 13
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 4
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 4
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 4
- 239000011575 calcium Substances 0.000 claims abstract description 4
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 4
- 235000008434 ginseng Nutrition 0.000 claims abstract description 4
- 240000005979 Hordeum vulgare Species 0.000 claims abstract description 3
- 235000007340 Hordeum vulgare Nutrition 0.000 claims abstract description 3
- 240000006394 Sorghum bicolor Species 0.000 claims abstract description 3
- 235000011684 Sorghum saccharatum Nutrition 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 11
- 239000004480 active ingredient Substances 0.000 claims description 6
- 244000020518 Carthamus tinctorius Species 0.000 claims description 4
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims description 4
- 235000013527 bean curd Nutrition 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 244000131316 Panax pseudoginseng Species 0.000 claims description 3
- 235000021329 brown rice Nutrition 0.000 claims description 2
- 239000004464 cereal grain Substances 0.000 claims description 2
- 239000004576 sand Substances 0.000 claims description 2
- 230000000459 effect on growth Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 11
- 235000013305 food Nutrition 0.000 abstract description 4
- 230000036541 health Effects 0.000 abstract description 3
- 241000196324 Embryophyta Species 0.000 abstract 2
- 241000208340 Araliaceae Species 0.000 abstract 1
- 241001632410 Eleutherococcus senticosus Species 0.000 abstract 1
- 241000628997 Flos Species 0.000 abstract 1
- 241001192908 Phlomis umbrosa Species 0.000 abstract 1
- 244000197580 Poria cocos Species 0.000 abstract 1
- 235000008599 Poria cocos Nutrition 0.000 abstract 1
- 240000005498 Setaria italica Species 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 235000002252 panizo Nutrition 0.000 abstract 1
- 210000000582 semen Anatomy 0.000 abstract 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 35
- 240000006891 Artemisia vulgaris Species 0.000 description 35
- 239000011248 coating agent Substances 0.000 description 22
- 238000000576 coating method Methods 0.000 description 22
- 238000009472 formulation Methods 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 239000012141 concentrate Substances 0.000 description 14
- 235000008504 concentrate Nutrition 0.000 description 14
- 239000013641 positive control Substances 0.000 description 14
- 239000000243 solution Substances 0.000 description 13
- 238000012360 testing method Methods 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 9
- 238000009792 diffusion process Methods 0.000 description 9
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 7
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 7
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 239000011574 phosphorus Substances 0.000 description 7
- 229910052698 phosphorus Inorganic materials 0.000 description 7
- 244000241838 Lycium barbarum Species 0.000 description 6
- 235000015459 Lycium barbarum Nutrition 0.000 description 6
- 230000003796 beauty Effects 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 235000015468 Lycium chinense Nutrition 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 239000008199 coating composition Substances 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 208000037824 growth disorder Diseases 0.000 description 5
- 241000411851 herbal medicine Species 0.000 description 5
- 230000001953 sensory effect Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000010411 cooking Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 241000251468 Actinopterygii Species 0.000 description 3
- 206010010356 Congenital anomaly Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 208000021017 Weight Gain Diseases 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000004584 weight gain Effects 0.000 description 3
- 235000019786 weight gain Nutrition 0.000 description 3
- ZHGNHOOVYPHPNJ-UHFFFAOYSA-N Amigdalin Chemical compound FC(F)(F)C(=O)OCC1OC(OCC2OC(OC(C#N)C3=CC=CC=C3)C(OC(=O)C(F)(F)F)C(OC(=O)C(F)(F)F)C2OC(=O)C(F)(F)F)C(OC(=O)C(F)(F)F)C(OC(=O)C(F)(F)F)C1OC(=O)C(F)(F)F ZHGNHOOVYPHPNJ-UHFFFAOYSA-N 0.000 description 2
- 241000252233 Cyprinus carpio Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000037182 bone density Effects 0.000 description 2
- 230000008468 bone growth Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000004217 heart function Effects 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 230000036299 sexual function Effects 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 238000004260 weight control Methods 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 description 1
- 235000003097 Artemisia absinthium Nutrition 0.000 description 1
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 description 1
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- KVSNMTUIMXZPLU-UHFFFAOYSA-N D:A-friedo-oleanane Natural products CC12CCC3(C)C4CC(C)(C)CCC4(C)CCC3(C)C2CCC2(C)C1CCCC2C KVSNMTUIMXZPLU-UHFFFAOYSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 206010049290 Feminisation acquired Diseases 0.000 description 1
- 208000034793 Feminization Diseases 0.000 description 1
- JUUHNUPNMCGYDT-UHFFFAOYSA-N Friedelin Natural products CC1CC2C(C)(CCC3(C)C4CC(C)(C)CCC4(C)CCC23C)C5CCC(=O)C(C)C15 JUUHNUPNMCGYDT-UHFFFAOYSA-N 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010024604 Lipoatrophy Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 240000001439 Opuntia Species 0.000 description 1
- 235000013389 Opuntia humifusa var. humifusa Nutrition 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000005107 Premature Birth Diseases 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 101000868151 Rattus norvegicus Somatotropin Proteins 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002019 anti-mutation Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000001138 artemisia absinthium Substances 0.000 description 1
- 239000001522 artemisia absinthium l. herb extract Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 235000012206 bottled water Nutrition 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- 229940069978 calcium supplement Drugs 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 229910052571 earthenware Inorganic materials 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 229930190029 eleutheroside Natural products 0.000 description 1
- 239000008769 eleutheroside Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- -1 etc. may be used Chemical compound 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- OFMXGFHWLZPCFL-SVRPQWSVSA-N friedelin Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3CCC(=O)[C@@H]1C OFMXGFHWLZPCFL-SVRPQWSVSA-N 0.000 description 1
- MFVJCHSUSSRHRH-UHFFFAOYSA-N friedeline Natural products CC1(C)CCC2(C)CCC3C4(C)CCC5C(C)(C)C(=O)CCC5(C)C4CCC3(C)C2C1 MFVJCHSUSSRHRH-UHFFFAOYSA-N 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000011868 grain product Nutrition 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 230000032724 odontogenesis Effects 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000021395 porridge Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940119569 wormwood extract Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 성장 또는 성장 호르몬 분비를 촉진하는 효과를 갖는, 인진쑥 함유 조성물 및 이를 이용하여 코팅된 기능성 코팅 곡류, 상기 코팅 곡류의 제조방법 및 상기 코팅 곡류를 이용하여 제조된 기능성 곡류 가공품에 관한 것이다.The present invention relates to a composition containing phosphorus mugwort having an effect of promoting growth or secretion of growth hormone, and a functional coated grains coated using the same, a method of preparing the coated grains, and a processed cereals manufactured using the coated grains.
최근 우리 사회는 경제 성장으로 인한 식습관의 변화와 영양상태의 개선으로 인해 소아와 청소년의 발육상태가 크게 개선되고 있다. 또한 큰 키를 선호하는 사회적 분위기가 형성되어 성장장애 환자 뿐 아니라 정상 소아에 있어서도 키 성장을 촉진시키는데 관심이 높아지고 있다. 이를 위한 성장촉진 방법으로는 성장호르몬 투여, 또는 이와 함께 갑상선 호르몬, 비타민 D, 인슐린 양성인자 등을 투여하는 방법이 있으며(Klaus G et al.,Pediatr. Nephrol..14: 612-615(2000)), 일리자노프 수술 및 기능성 식품 복용 등의 방법이 주로 사용되고 있다. 그러나 현재 사용되는 이들 방법은 여러 가지 문제점을 가지고 있다. 예를 들어, 성장 호르몬 투여에 따른 부작용으로는 주사부위의 소양감, 발적, 동통, 지방위축과 고혈압, 당 불내성, 췌장염, 전신 알레르기 반응, 성장 호르몬 항체 양성, 암 발생 및 남성의 여성화로 인한 유방 발달 등의 증상이 나타난다. 일리자노프 수술은 양측 하지 길이가 비대칭인 경우에 주로 사용되는 방법인데, 이를 키가 작은 사람에게 적용하여 양쪽 다리 모두를 억지로 늘릴 경우, 환자의 고통이나 사회적 비용손실은 감수하더라도 예상치 못한 부작용으로 인해 정상보행을 하지 못하는 경우도 발생될 수 있다.In recent years, the development of children and adolescents has been greatly improved due to changes in eating habits and nutritional status due to economic growth. In addition, a social atmosphere that favors large height has been formed, and interest in promoting height growth is increasing in normal children as well as patients with growth disorders. Growth promotion methods for this purpose include the administration of growth hormone or thyroid hormone, vitamin D, insulin positive factors, etc. (Klaus G et al., Pediatr. Nephrol .. 14 : 612-615 (2000) ), Ilizanov surgery and functional foods are mainly used. However, these methods currently used have various problems. For example, side effects from growth hormone administration include pruritus, redness, pain, fat atrophy and hypertension, glucose intolerance, pancreatitis, systemic allergic reactions, growth hormone antibody positive, cancer development, and feminization in men. Back symptoms appear. Ilizanov surgery is commonly used for asymmetric bilateral lower limb lengths.If it is applied to a shorter person and is forced to stretch both legs, the patient's pain or social cost may be lost due to unexpected side effects. Failure to walk normally can also occur.
전통적으로 한의학에서는 소아 성장 장애의 원인을 선천적 요인과 후천적 요인으로 분류하고 있으며, 신(腎)은 "선천지본(先天之本)"이라 하여 장정(藏精), 주골(主骨), 생수(生髓), 뇌수지해(腦髓之海)의 근본이 되고, 비(脾)는 "후천지본(後天之本)"이라 하여 주기육(主肌肉), 주사지(主四肢), 주기혈화생지원(主氣血化生之原)이 된다고 하였다. 또한 신기(腎氣)가 충식(充實)하고 비기(脾氣)가 건운(健運)하면 생장 발육이 양호한 반면 선천부족(先天不足)과 후천실조(後天失調)가 생기면 생장발육에 장애를 초래하여 체중, 신장, 치아발생, 동작, 지능 등 여러 방면에 영향을 미친다고 보고된 바 있다(홍원식,정교황제내경소문(精交皇帝內經素問), 서울, 동양의학연구원출판사, pp11, 24, 34, 39, 69, 166, 333(1985)). 이러한 성장장애의 일종으로 '오지(五遲)'와 '오연(五軟)' 등이 있는데, 오지(五遲)는 소아의 입지(立遲), 행지(行遲), 발지(髮遲), 치지(齒遲), 어지(語遲)로 발육이 지연되어 행동이나 언어 및 치아성장의 장애를 말하고, 오연(五軟)은 두연(頭軟), 항연(項軟), 수각연(手脚軟), 기육연(肌肉軟), 구연(口軟)으로 대개 선천적인 체질의 허약, 조산 또는 후천적인 영양부족으로 인한 대뇌발육부전 등의 성장장애를 말한다. 성장 장애의 한의학적인 치료법으로는 보익법(補益法)(보기(補氣), 보혈(補血), 보양(補陽), 보음(補陰)), 활혈화어법(活血化瘀法), 온과거한법 등이 있으며 이중 보익법(補益法)이 가장 중요하다고 알려져 있다.Traditionally, Chinese medicine classifies the causes of pediatric growth disorders into congenital and acquired factors, and Shin is known as the "born natural book" in the form of Jangjeong, Jugol, and bottled water. It is the basis of the 生, and the cerebrospinal fluid sea, and the rain is called the "fucheonjibon", which means the main meat, the injection paper, and the main blood metabolism. It is said to be a support (主 氣血 化生 之 原). In addition, the growth of the body is good when the nourishment is good and the dryness is dry. However, the lack of congenital and post-acquired dysfunction causes the growth to be impaired. , Kidney, tooth development, movement, intelligence, etc. have been reported (Hong Won-sik, Emperor's Endooral Rumors, Seoul, Institute of Oriental Medicine, pp11, 24, 34, 39, 69, 166, 333 (1985)). There are two types of growth disorders, 'Oji' and 'Ohyeon'. The Oji is the location of children, their habits, and their feet. , Development, delayed development of the larvae and eoji, and impaired behavior, language, and tooth growth. Oh Yeon (軟) refers to yeonyeon (항), hangyeon (수), Hakyeonyeon (手脚) 성장), yukyeonyeon (肌肉 軟), cough (口 軟) usually refers to growth disorders, such as cerebral dysfunction due to congenital weakness, premature birth or acquired malnutrition. Herbal treatments for growth disorders include Boik ((), Blood (Blood), Boyang (보 陽), Boeum (補陰), Live Blood Chemistry (Activ 血 化 온 法), Warm There are past Korean laws, and the double reward law is known to be the most important.
이와 같은 한의학적 이론에 근거하여 시판 중인 건강 보조 식품은 주로 가시오갈피, 오가피, 홍화씨, 두충, 백복령, 토사자, 복분자, 녹각 등을 원료로 한다. 가시오갈피의 경우 주요 성분은 엘로테로사이드(eleutheroside) A∼E로 알려져 있으며, 이외에 클로로젠산(chlorogenic acid), β-시토스테롤(β-sitosterol), 프리에델린(friedelin), 베툴린산(betulinic acid), 아미그달린(amygdalin), 이오스프락시딘(iosfraxidin) 등이 함유되어 있다. 가시오갈피는 골길이 성장 촉진 효과 등으로 연구가 이루어진 바 있으며(박선영 외 5명,한국생약학회 심포지엄 초록집, 2002), 홍화씨, 두충, 백복령, 복분자, 토사자 및 녹각과 칼슘을 포함하는 성장촉진용 건강보조식품(대한민국 특허 제 0278206 호)도 이미 시판 중이다.On the basis of the traditional Chinese medicine theory, the dietary supplements on the market are mainly composed of prickly pear, ogapi, safflower seed, tofu, baekbokyeong, earth and sand, bokbunja, and green tea. In the case of psorigalpi, the main components are known as eleutherosides A to E. In addition, chlorogenic acid, β-sitosterol, friedelin, and betulinic acid , Amigdalin, iosfraxidin and the like. Psoriasis has been studied for its bone-growth-promoting effect (Park Sun-young and five others, Korean Society for Pharmacy Symposium , 2002), and health promotion for growth including safflower seed, tofu, baekbokyeong, bokbunja, earthenware and greenery and calcium Supplements (Korean Patent No. 0278206) are already commercially available.
한편, 성장 호르몬은 노화진전에 따른 장기의 재성장, 단백질 합성 증가 및 분해 억제, 지방을 분해하여 비만 치료, 면역기능 향상 및 에너지 효율 향상, 신장 기능 향상, 뼈 성장, 골밀도 증가, 혈압 저하, 심장 기능 향상, LDL 낮추고 HDL 높임으로써 콜레스테롤 감소, 시력보강 및 기억력 향상, 성기능 향상, 상처 치유력 향상시킴, 피부 상태 향상 및 주름제거의 목적으로 투여하고 있다.On the other hand, growth hormones reorganize organs according to aging progress, increase protein synthesis and inhibit degradation, break down fat to treat obesity, improve immune function and energy efficiency, improve kidney function, bone growth, increase bone density, decrease blood pressure, cardiac function It is administered for the purpose of reducing cholesterol, improving LDL and improving memory, improving sexual function, improving wound healing, improving skin condition and removing wrinkles by lowering LDL and raising HDL.
따라서 본 발명자들은 성장 또는 성장호르몬의 분비를 촉진할 수 있는 약물을 개발하기 위해 연구하던 중 안전하고 독성이 없으며 다양한 약리 작용을 하는 인진쑥(Artemisia capillarisThunberg.)이 성장을 촉진하거나 성장호르몬의 분비를 촉진시킬 수 있음을 발견하여 본 발명을 완성하였다.Therefore, the inventors of the present invention while researching to develop a drug that can promote growth or secretion of growth hormone, Artemisia capillaris Thunberg, which has a safe, nontoxic, and various pharmacological action, promotes growth or secretes growth hormone. The present invention has been completed by discovering that it can be promoted.
인진쑥은 열을 내리고 습을 제거하는 효과가 있어, 습열 황달, 소변이 잘 나오지 않는 증상을 치료하는데 효과가 있는 것으로 알려져 있는데, 이의 약리작용으로는 간손상 억제 작용(이치호 외 2명,한국축산식품학회 제22차 추계학술발표회 초록집, 1998), 항암효과(정차권 외 3명,학국식품과학회 춘계 공동학술발표회 초록집, 1998), 항산화 작용, 혈중지질 감소 및 간기능 개선효과(한은경 외 4명,학국식품영양과학회 춘계학술대회, 1997), 항돌연변이 효과(최동성 외 5명,한국생물공학회지, 2000), 항균효과(장매희 및 조연희,인진쑥, 사철쑥, 사자발쑥의 정유성분 및 항균효과) 등이 알려져 있다.Injin mugwort has the effect of lowering heat and eliminating moistness, and is known to be effective in treating the symptoms of moist jaundice and poor urine, and its pharmacological action is to inhibit liver damage (Ichiho et al., Two livestock foods). Society's 22nd Fall Conference Abstract Collection, 1998), Anticancer Effect (3 persons including Jung-Gwon Chung, Hakkuk Food Science Association Spring Conference Abstract Collection , 1998), antioxidant activity, blood lipid reduction and liver function improvement effect (Han Eun-kyung and 4 others, Hakkuk) Food Science and nutrition Conference, 1997), anti-mutation effect (five other choedongseong, Korea Society for Biotechnology and Bioengineering paper, 2000), and antibacterial effects (jangmaehui and essential components and antibacterial effects of wormwood joyeonhui, injinssuk, sacheolssuk, sajabal), etc. are known have.
그러나, 지금까지 인진쑥의 성장 또는 성장호르몬의 분비 촉진효과는 보고된 바 없다.However, there has been no report on the effect of growth or secretion of growth hormone of Injin mugwort.
따라서, 본 발명의 목적은 성장 또는 성장호르몬의 분비를 촉진하는 조성물을 제공하는 것이다.Accordingly, it is an object of the present invention to provide a composition that promotes growth or secretion of growth hormone.
본 발명의 다른 목적은 상기 조성물이 코팅된 기능성 코팅 곡류, 이의 제조방법 및 이를 이용한 기능성 곡류 가공품을 제공하는 것이다.Another object of the present invention is to provide a functional coated grains coated with the composition, a method of manufacturing the same, and a functional cereal processed product using the same.
상기 목적을 달성하기 위하여, 본 발명에서는 인진쑥 추출물을 유효성분으로 포함하는, 성장 또는 성장호르몬 분비 촉진용 조성물을 제공한다.In order to achieve the above object, the present invention provides a composition for promoting growth or secretion of growth hormone comprising the extract of jinjinjin as an active ingredient.
상기 다른 목적을 달성하기 위하여, 본 발명에서는 상기 조성물로 코팅된 성장 또는 성장호르몬 분비 촉진에 효과가 있는 기능성 코팅 곡류 및 이를 이용하여 제조된 기능성 곡류 가공품을 제공한다.In order to achieve the above another object, the present invention provides a functional coated cereals and functional cereals manufactured using the same, which are effective in promoting growth or secretion of growth hormone coated with the composition.
또한, 본 발명에서는 상기 곡류코팅 조성물을 곡류에 첨가하여 혼합한 다음 건조하는 것을 특징으로 하는 기능성 코팅 곡류의 제조방법을 제공한다.In addition, the present invention provides a method for producing a functional coated grains, characterized in that the grain coating composition is added to the grains, mixed and dried.
본 발명의 조성물은 성장 또는 성장 호르몬 분비 촉진효과를 위한 유효성분으로서 인진쑥 추출물을 포함한다. 인진쑥 추출물은 30∼50 메쉬로 분쇄한 인진쑥을 3 내지 6배 중량비의 물 또는 유기용매 중에서 48 내지 72시간 동안 초음파 분쇄기를 이용하여 추출하거나 4 내지 7 시간 동안 환류한 다음, 필요에따라 0.1 내지 10 ㎛ 필터로 여과한 후 60 내지 80 ℃ 온도에서 24 내지 60 시간 동안 5 내지 10 배 감압농축하여 30℃ 이하로 냉각함으로써 수득할 수 있다. 사용가능한 추출물의 품질은 20 내지 50 브릭스(brix)이다. 이 때 유기용매로는 에탄올, 메탄올, 이소프로필 알콜과 같은 저급 알콜 또는 이들의 50% 이상 수용액, 또는 주정 등을 사용할 수 있으며, 특히 주정 또는 70% 에탄올이 바람직하다.The composition of the present invention comprises the extract of Injin mugwort as an active ingredient for promoting growth or secretion of growth hormone secretion. Phosphorus mugwort extract is extracted with an ultrasonic grinder for 48 to 72 hours or refluxed for 4 to 7 hours in water or an organic solvent of 3 to 6 times the weight ratio of pulverized mugwort pulverized to 30-50 mesh, and then 0.1 to 10 as necessary After filtration with a 탆 filter it can be obtained by concentrating under reduced pressure 5 to 10 times at 60 to 80 ℃ temperature for 24 to 60 hours to cool to 30 ℃ or less. The quality of the extracts that can be used is 20 to 50 brix. In this case, as the organic solvent, lower alcohols such as ethanol, methanol, isopropyl alcohol, 50% or more of aqueous solution thereof, or alcohol, etc. may be used, and alcohol or 70% ethanol is particularly preferable.
본 발명의 조성물은 성장 호르몬 분비를 촉진시킴으로써 노화진전에 따른 장기의 재성장, 단백질 합성 증가 및 분해 억제, 지방을 분해하여 비만 치료, 면역기능 향상 및 에너지 효율 향상, 신장 기능 향상, 뼈 성장, 골밀도 증가, 혈압 저하,심장 기능 향상, LDL은 낮추고 HDL은 높임으로써 콜레스테롤 감소, 시력보강 및 기억력 향상, 성기능 향상, 상처 치유력 향상, 피부 상태 향상 및 주름 제거 등에 효과가 있다.The composition of the present invention by promoting the growth hormone secretion, regrowth of organs according to the aging progress, protein synthesis and inhibition of degradation, fat degradation to treat obesity, immune function and energy efficiency, kidney function, bone growth, bone density increase Lowering blood pressure, improving heart function, lowering LDL and increasing HDL are effective in reducing cholesterol, enhancing vision and memory, improving sexual function, improving wound healing, improving skin condition and removing wrinkles.
본 발명의 조성물은 약리효과를 증진시키기 위해 약학적으로 허용되는 다른 생약재 또는 그의 추출물을 추가로 포함할 수 있다. 이 경우, 상기 추출방법에 따라 생약재의 추출물을 제조한 후 약학 조성물에 가하거나 인진쑥과 생약재를 혼합한 후 상기 방법으로 추출하여 얻어진 추출물을 조성물에 포함시킬 수도 있다.The composition of the present invention may further include other pharmaceutically acceptable herbal medicines or extracts thereof to enhance the pharmacological effect. In this case, an extract of the herbal medicine may be prepared according to the extraction method and then added to the pharmaceutical composition, or the extract obtained by extracting by the above method after mixing Injin mugwort and the herbal medicine may be included in the composition.
본 발명의 조성물에 추가될 수 있는 생약재는 약학적으로 허용되는 임의의 생약재일 수 있으며, 예를 들면, 오가피, 가시오갈피, 속단, 구기자, 홍화씨, 두충, 백복령, 복분자, 토사자 및 인삼을 각각 단독으로 또는 배합하여 사용할 수 있다. 또한, 본 발명의 조성물은 약리효과 증진을 위해 녹각 또는 칼슘을 더 포함할 수도 있다.The herbal medicine that may be added to the composition of the present invention may be any pharmaceutically acceptable herbal medicine, for example, Ogapi, prickly gallop, sokdan, wolfberry, safflower seed, tofu, baekbokyeong, bokbunja, tosa and ginseng, respectively Or can be used in combination. In addition, the composition of the present invention may further comprise a rust or calcium to enhance the pharmacological effect.
인진쑥 추출물은 전체 조성물 중량을 기준으로 10 내지 100 중량%, 바람직하게는 20 내지 50 중량%의 양으로 포함할 수 있으며, 생약재 추출물, 또는 녹각 또는 칼슘을 전체 조성물 중량의 0 내지 90 중량%, 바람직하게는 50 내지 80 중량%의 양으로 포함시킬 수 있다.Phosphorus mugwort extract may be included in an amount of 10 to 100% by weight, preferably 20 to 50% by weight, based on the total weight of the composition, 0 to 90% by weight of the herbal extract, or greenery or calcium, preferably Preferably in an amount of 50 to 80% by weight.
성장 또는 성장호르몬의 분비 촉진을 위해서, 인진쑥 추출물은 이를 포함하는 조성물의 형태로 포유동물에게 투여되고, 이 조성물은 약학 조성물 또는 기능성 코팅 곡류 제조를 위한 곡류 코팅용 조성물일 수 있다.In order to promote the secretion of growth or growth hormone, the extract of the ginseng worm is administered to the mammal in the form of a composition comprising the composition, which may be a pharmaceutical composition or a composition for grain coating for the production of functional coating grains.
본 발명의 약학 조성물을 이용하여 통상적인 방법에 따라 약학 제형을 제조할 수 있다. 제형의 제조에 있어, 활성 성분인 인진쑥 추출물을 담체와 함께 혼합 또는 희석하거나, 용기 형태의 담체내에 봉입시키는 것이 바람직하다. 담체가 희석제로 사용되는 경우에는 활성 성분에 대한 비히클, 부형제 또는 메디움으로 작용하는 고형, 반고형 또는 액상의 물질일 수 있다. 따라서, 제형은 정제, 환제, 분제, 새세이, 엘릭시르, 현탁제, 유제, 용액제, 시럽제, 에어로졸, 연질 또는 경질 젤라틴 캅셀제, 멸균 주사제, 멸균 분제 등의 형태일 수 있다. 적합한 담체, 부형제 및 희석제의 예로는, 락토즈, 덱스트로즈, 수크로즈, 솔비톨, 만니톨, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로즈, 폴리비닐피롤리돈, 물, 메틸하이드록시벤조에이트, 프로필하이드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다. 제형은 충진제, 항응집제, 윤활제, 습윤제, 향료, 유화제, 방부제 등을 추가로 포함할 수 있다. 본 발명에 따른 약학 조성물은 포유 동물에 투여된 후 활성 성분의 신속, 지속 또는 지연된 방출을 제공할 수 있도록 당업계에 잘 알려진 방법을 사용하여 제형화될 수 있다.The pharmaceutical compositions of the present invention can be used to prepare pharmaceutical formulations according to conventional methods. In the preparation of the formulation, it is preferable to mix or dilute the active ingredient, Phosphorus mugwort extract with the carrier, or to enclose it in a carrier in the form of a container. When the carrier is used as a diluent, it may be a solid, semisolid or liquid substance which acts as a vehicle, excipient or medium for the active ingredient. Thus, the formulations may be in the form of tablets, pills, powders, assays, elixirs, suspensions, emulsions, solutions, syrups, aerosols, soft or hard gelatin capsules, sterile injectables, sterile powders and the like. Examples of suitable carriers, excipients and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, Propylhydroxybenzoate, talc, magnesium stearate and mineral oil. The formulation may further comprise fillers, anti-coagulants, lubricants, wetting agents, fragrances, emulsifiers, preservatives and the like. Pharmaceutical compositions according to the invention can be formulated using methods well known in the art to provide rapid, sustained or delayed release of the active ingredient after administration to a mammal.
본 발명에 따른 약학 조성물은 경구, 경피, 피하, 정맥 또는 근육을 포함한 여러 경로를 통해 투여될 수 있다. 사람의 경우, 통상적인 1일 투여량은 0.1 내지 100 ㎎/㎏ 체중의 범위일 수 있고, 1회 또는 수회로 나누어 투여할 수 있다. 그러나, 실제 투여량은 투여 경로, 환자의 연령, 성별 및 체중, 건강상태 및 질환의 중증도 등의 여러 관련 인자에 비추어 결정되어야 한다.The pharmaceutical compositions according to the invention can be administered via several routes including oral, transdermal, subcutaneous, intravenous or intramuscular. For humans, typical daily dosages can range from 0.1 to 100 mg / kg body weight and can be administered once or in divided doses. However, the actual dosage should be determined in light of several relevant factors such as the route of administration, the age, sex and weight of the patient, the state of health and the severity of the disease.
또한, 본 발명의 곡류 코팅용 조성물에서는 취사 시 백미가 호화되면서 팽창될 때 코팅액이 같이 팽창되지 않아 떨어져 나가는 코팅액의 확산현상을 방지하기위하여 10 내지 50 % 농도의 전분용액을 조성물에 추가로 첨가하여 곡류의 팽창과 동시에 코팅액도 같이 팽창할 수 있도록 함으로써 코팅액의 확산을 방지할 수 있다.In addition, in the composition for grain coating of the present invention, a starch solution having a concentration of 10 to 50% is additionally added to the composition in order to prevent diffusion of the coating solution, which does not expand when the white rice is expanded as it is expanded while cooking. It is possible to prevent the diffusion of the coating liquid by allowing the coating liquid to expand together with the expansion of the grains.
본 발명의 곡류 코팅용 조성물에는 전체 조성물 중량에 대하여 전분용액을 5 내지 50 중량%, 바람직하게는 5 내지 15 중량%의 양으로 첨가할 수 있다.The starch solution may be added to the composition for grain coating of the present invention in an amount of 5 to 50% by weight, preferably 5 to 15% by weight based on the total weight of the composition.
본 발명에서 사용될 수 있는 곡류로는 백미, 현미, 보리, 조, 수수, 찹쌀 등이 포함된다.Grains that may be used in the present invention include white rice, brown rice, barley, crude, sorghum, glutinous rice and the like.
또한, 본 발명에서는 상기 곡류코팅 조성물을 곡류 1 ㎏당 10 내지 250 g의 양, 바람직하게는 20 내지 200 g의 양으로 곡류에 첨가하여 혼합한 다음 30 내지 60 ℃에서 30 분 내지 2 시간 건조함으로써 성장 또는 성장호르몬 분비 촉진효과를 갖는 기능성 코팅 곡류를 제조할 수 있다. 또한, 이를 이용하여 죽, 밥, 떡 및 즉석밥 등의 다양한 곡류 가공품을 제조할 수 있다.In addition, in the present invention, the grain coating composition is added to the grains in an amount of 10 to 250 g, preferably 20 to 200 g, per 1 kg of cereal grains, mixed and then dried at 30 to 60 ° C. for 30 minutes to 2 hours. Functional coated grains having a growth or growth hormone secretion promoting effect can be prepared. In addition, it can be used to produce a variety of cereal products, such as porridge, rice, rice cakes and instant rice.
본 발명의 기능성 코팅 곡류는 우수한 성장 또는 성장호르몬 분비 촉진효과를 나타낼 뿐만 아니라 취사 시 코팅액의 확산이 일어나지 않고, 일반미와 비교할 때 관능평가 결과도 우수하여 기능성 보조식품으로 널리 사용될 수 있다.The functional coated grains of the present invention not only exhibit excellent growth or growth hormone secretion promoting effect but also do not cause diffusion of the coating solution during cooking, and have excellent sensory evaluation results when compared to general rice, and thus can be widely used as functional supplements.
이하 하기 실시예에 의하여 본 발명을 좀더 상세하게 설명하고자 한다. 단. 하기 실시예는 본 발명을 예시하기 위한 것일 뿐 본 발명의 범위가 이들만으로 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail with reference to the following examples. only. The following examples are only for illustrating the present invention, but the scope of the present invention is not limited thereto.
실시예 1 내지 5: 인진쑥 추출물을 포함하는 조성물의 제조Examples 1 to 5: Preparation of a composition comprising a ginko wormwood extract
건조된 인진쑥, 오가피, 속단, 구기자를 30 내지 50 메쉬로 분쇄하였다. 하기와 표 1과 같은 구성으로 이루어진 각 조성분 1 g에 5 ㎖ 70% 에탄올을 가하고 30 ℃에서 48 시간 초음파 분쇄기를 이용하여 추출한 후 액체 성분을 모두 증발시켰다. 남은 고형 성분에 50% 에탄올 5㎖를 넣어 볼텍서(vortexer)를 이용하여 10분간 혼합한 후 추출물로 사용하였다. 실시예 1의 농축액은 증발 후 남은 고형 성분에 50% 에탄올을 5㎖, 1.7㎖, 1㎖, 0.5㎖을 넣어 각각 1배, 3배, 5배, 10배 농축액을 만들어 사용하였다.Dried phosphorus mugwort, staphylococcus, fast, and wolfberry were ground to 30-50 mesh. 5 ml 70% ethanol was added to 1 g of each component having the composition shown in Table 1 below and extracted using an ultrasonic grinder at 30 ° C. for 48 hours, and then all the liquid components were evaporated. 5 ml of 50% ethanol was added to the remaining solid components and mixed for 10 minutes using a vortexer, which was then used as an extract. In the concentrate of Example 1, 5 ml, 1.7 ml, 1 ml, and 0.5 ml of 50% ethanol was added to the solid component remaining after evaporation, and the concentrates were used to make 1-fold, 3-fold, 5-fold, and 10-fold concentrates, respectively.
시험예 1 : 세포 증식 시험 - 성장호르몬 분비 촉진 효능 시험Test Example 1 cell proliferation test-growth hormone secretion promoting efficacy test
생체 외(In vitro) 성장호르몬 분비 촉진 효과를 다음과 같은 방법으로 측정하였다. 즉, 뇌하수체 세포를 계대배양할 수 있도록 세포주화 된 GH4C1(ATCC CCL-82.2) 세포주 2 ×106개의 세포에 상기 실시예 1 내지 5에서 수득된 각 추출물을 50 ㎕의 양으로 가하고 Ham's F12 배지에서 37 ℃로 1 시간 동안 배양하여 성장호르몬을 분비시켰다. 성장호르몬을 함유하는 배양액을 토끼에서 직접 분리시킨 토끼의 연골세포(chondrocyte)와 37 ℃에서 4 시간 동안 배양한 후 MTT 분석방법(Kaiyoun Cai al.,Biomaterials,23:1153-1160(2002))을 이용하여 세포의증식정도를 측정함으로써 성장호르몬 분비 촉진 정도를 관찰하였다. 세포의 증식정도는 수용성 테트라졸륨 염으로부터 세포의 미토콘드리아에 있는 탈수소효소(dehydrogenase)에 의해 형성된 불용성의 자주색 포르마잔(formazan)을 이소프로판올로 추출하여 570 nm 분광광도계 상에서 흡광도(O.D.)를 측정하여 확인하였다. In vitro growth hormone secretion promoting effect was measured by the following method. In other words, 50 μl of each extract obtained in Examples 1 to 5 was added to 2 × 10 6 cells of the GH4C1 (ATCC CCL-82.2) cell line cell lined for passage of pituitary gland cells, and in Ham's F12 medium. The growth hormone was secreted by incubating for 1 hour at 37 ℃. After incubating the culture medium containing growth hormone with chondrocytes of rabbits directly isolated from rabbits for 4 hours at 37 ° C, MTT assay (Kaiyoun Cai al., Biomaterials , 23 : 1153-1160 (2002)) was performed. By measuring the proliferation of the cells using the growth hormone secretion was observed. The proliferation of the cells was determined by extracting insoluble purple formazan formed from dehydrogenase in the mitochondria of the cells with isopropanol from the water-soluble tetrazolium salt and measuring the absorbance (OD) on a 570 nm spectrophotometer. .
따라서, 흡광도(O.D.) 값이 높을수록 세포의 증식이 많이 되었다고 볼 수 있으며, 이는 성장 호르몬 분비 촉진 정도가 크다고 볼 수 있다. 음성대조군으로서는 상기 동일 세포주에 70% 에탄올을 50㎕의 양으로 넣어 배양하여 사용하였으며, 양성 대조군은 성장호르몬 분비를 촉진하게 하는 물질인 GHRF(Growth hormone releasing factor : G6646, sigma)를 50㎕의 양으로 사용하여 배양하였다,Therefore, the higher the absorbance (O.D.) value can be seen that the more proliferation of cells, which can be seen as a greater growth hormone secretion. As a negative control group, 50% of 70% ethanol was added and cultured in the same cell line, and the positive control group was used in an amount of 50 μl of GHRF (Grow46 hormone, sigma), which promotes growth hormone secretion. Incubated with,
상기 표 2에서와 같이, 본 발명의 인진쑥 추출물 함유 군에서 성장 호르몬의 분비가 촉진되는 경향을 보였으며, 인진쑥과 다른 기타 성분의 혼합으로도 성장 호르몬 분비가 촉진됨을 볼 수 있었다. 그러나, 인진쑥의 농도와 성장 호르몬 분비는 비례적이지 않음을 알 수 있었다.As shown in Table 2, the growth hormone secretion in the group containing the extract of the present invention showed a tendency to be promoted, the growth hormone secretion was also promoted by the mixing of phosphorus and other components. However, the concentration of phosphorus mugwort and growth hormone secretion were not proportional.
시험예 2: 성장 촉진 시험 - 랫트 시험Test Example 2: Growth Acceleration Test-Rat Test
5주령의 SPF 스프라그 다울리 랫트(Sprague Dauley rat, (주) 샘타코 바이오코리아)를 7일간 순화시킨 후 발육이 정상이고 건강한 랫트를 각 군당 암, 수 각각 5마리씩 배정하였다.Five-week-old SPF Sprague Dauley rats (Sampaco BioKorea) were purified for 7 days, and normal and healthy rats were assigned to each of five females and males.
실시예 1에서 제조된 인진쑥 1배 농축액을 동결건조한 후 시험군의 랫트에 각각 50 ㎎/㎏, 100 ㎎/㎏,300㎎/㎏ 및 500 ㎎/㎏이 되도록 물 6㎖에 첨가하여 물 240㎖에 섞어 매일 음수로 자유급이시켰다. 대조군은 물만을 사용하였으며, 양성대조군에는 소성장 호르몬(bovine somatotropin)(입수처:LG 화학)을 임상적용 용량인 1.2mg/kg/14일을 기준으로 하여 2주마다 한번씩 피하 투여하였다. 8주 동안 시험을 수행하였으며, 성장 촉진 정도를 확인하기 위해 체중은 2주마다 측정하였고, 성장 호르몬(GH) 및 인슐린-유사 성장인자-1(IGF-1)의 농도는 매달 측정하였다. 대조군과 각 투여군 사이의 유의성은 ANOVA 및 Dunnett-t 검정(Kaiyoun Cai al.,Biomaterials,23:1153-1160(2002))으로 비교하였다. GH의 농도는 랫트 성장 호르몬 RIA 키트(Linco Res., cat. # RGH 45-HK)를 이용하여 분석하였고, IGF-1의 측정은 IRMA(immunoradiometric assay) 방법(Conti, E., et al,J. Am. Coll. Cardiol., 38, 26-32)을 이용하였다.After freeze-drying the 1-fold concentrate of Injin mugwort prepared in Example 1, the rats of the test group were added to 6 ml of water to be 50 mg / kg, 100 mg / kg, 300 mg / kg and 500 mg / kg, respectively, and 240 ml of water. Mix in the daily free negative numbers. As the control group, only water was used, and the positive control group was subcutaneously administered once every two weeks based on the clinical application dose of 1.2 mg / kg / 14 days of bovine somatotropin (source: LG Chem). The test was performed for 8 weeks, body weights were measured every two weeks to determine the extent of growth promotion, and concentrations of growth hormone (GH) and insulin-like growth factor-1 (IGF-1) were measured monthly. Significance between the control group and each dose group was compared by ANOVA and Dunnett-t test (Kaiyoun Cai al., Biomaterials , 23 : 1153-1160 (2002)). The concentration of GH was analyzed using the rat growth hormone RIA kit (Linco Res., Cat. # RGH 45-HK), and the measurement of IGF-1 was measured by immunoadiometric assay (IRMA) method (Conti, E., et al, J). Am. Coll. Cardiol. , 38, 26-32).
하기 표 3 및 4에는 각각 수컷 및 암컷의 체중증가를, 표 5 및 6에는 GH 농도를, 표 7 및 8에는 IGF-1의 농도를 나타내었다.Tables 3 and 4 show male and female weight gains, Tables 5 and 6 show GH concentrations, and Tables 7 and 8 show IGF-1 concentrations.
상기 표 3 및 4에서 보듯이, 대조군의 수컷과 암컷의 체중 증가율은 각각 46.2% 및 36%이었으며, 소성장 호르몬을 투여한 양성 대조군의 경우는 50.4% 및 40.7% 증가함으로써 대조군의 증가율에 비하여 4~5% 높은 증가율을 나타내었다. 또한, 본 발명의 인진쑥 추출물을 투여한 경우는 대조군의 증가율과 비교하여 3~6% 높은 증가율을 보여 기존의 성장 호르몬과 동등한 효과를 나타냄을 알 수 있다.As shown in Tables 3 and 4, the male and female weight gains of the control group were 46.2% and 36%, respectively, and the positive control group administered with the ileal hormone increased 50.4% and 40.7%, respectively, compared to the increase rate of the control group. ~ 5% higher growth rate. In addition, when the administration of the extract of Injin mugwort of the present invention shows a 3 to 6% higher increase rate compared to the increase rate of the control group can be seen that the same effect as the existing growth hormone.
상기 표 5 및 6에서 보듯이, 양성 대조군의 경우 성장 호르몬 양의 증가율이 대조군에서의 성장 호르몬 양의 증가율에 비해 11~20% 높게 나타났다. 또한, 본 발명의 인진쑥 추출물을 투여한 경우에는 대조군의 성장 호르몬 양의 증가율에 비하여 7~17% 높게 나타났으며, 이는 양성 대조군보다도 우수한 결과임을 알 수 있다. 또한, 성장호르몬과 추출물의 양은 비례적인 관계를 가지고 있지 않지만 수컷과 암컷 모두 300 mg/kg의 인진쑥 추출물 농도에서 가장 좋은 결과를 나타냄을 알 수 있다.As shown in Tables 5 and 6, the growth rate of the growth hormone amount in the positive control group was 11 ~ 20% higher than the growth rate of the growth hormone amount in the control group. In addition, the administration of the extract of the present invention of the mugwort extract 7-17% higher than the increase rate of the growth hormone amount of the control group, which can be seen that the better results than the positive control group. In addition, the growth hormone and the amount of the extract does not have a proportional relationship, but both males and females can be seen that the best results at the concentration of 300 mg / kg of the extract.
상기 표 7 및 8에서 보듯이, IGF-1의 경우도 성장 호르몬과 마찬가지로 300mg/kg의 인진쑥 추출물 투여군에서 가장 좋은 효과를 보임을 볼 수 있었다.As shown in Tables 7 and 8, IGF-1 also showed the best effect in the 300 mg / kg jinsugui extract administration group, like growth hormone.
시험예 3: 잉어 성장 촉진 시험Test Example 3: Carp Growth Promotion Test
잉어 60 마리를 이용하여 공시어로 2주일 정도 적응시킨 후 각각 6군으로 나누어 2주 동안 자유식이시킨 후 체장 및 체중 증가율을 측정하여, 그 결과를 하기 표 9에 나타내었다. 즉, 각각 총 어체중의 2~3%의 일반 사료(대조군); 어체중의 2~3%의 일반 사료와 어류성장촉진제(바이오메이트, RNL 생명과학) 50mg 혼합 사료; 어체중의 2~3%의 일반 사료를 각각 10 ㎎/㎏, 30 ㎎/㎏, 50 ㎎/㎏ 및 100㎎/㎏ 의 인진쑥 추출물 1배 농축액(실시예 1)으로 코팅한 사료(실험군)을 투여하였다.After adapting for about two weeks using 60 carp as a co-seeker, divided into six groups and free diet for two weeks, the body length and weight increase rate were measured, and the results are shown in Table 9 below. That is, 2 to 3% of the general diet (control) of the total body weight; 2 to 3% of normal weight in fish and 50 mg of mixed feed for fish growth promoters (Biomate, RNL Life Sciences); Feeds (experimental group) coated with 2 ~ 3% of the normal feed of fish body with 10 mg / kg, 30 mg / kg, 50 mg / kg, and 100 mg / kg of the 1-fold concentrate of Injin mugwort extract (Example 1) Administered.
상기 표 9에서 보듯이, 50 mg/kg 이상의 인진쑥 추출물 투여군에서는 양성 대조군과 유사한 결과를 나타내었다. 이로부터 본 발명의 인진쑥 추출물은 체중증가 뿐만 아니라 체장 증가에도 효과가 있음을 알 수 있다.As shown in Table 9, 50 mg / kg or more of the Injin mugwort extract administration group showed similar results as the positive control. It can be seen that the extract of Injin mugwort of the present invention is effective in increasing body weight as well as body weight.
제제예: 기능성 코팅 곡류 제조 Formulation Example : Preparation of Functional Coated Grains
제제예 1 내지 4Formulation Examples 1 to 4
하기 표 10에 나타낸 조성과 같이, 상기 실시예 1에서 수득된 인진쑥 추출물 및 전분용액을 5:1의 중량비로 혼합하여 제조된 코팅 조성물을 이용하여 백미 1kg 당 200g의 양으로 백미를 코팅하였다. 코팅은 혼합기(입수처: RNL 생명과학(주)) 또는 코팅기(입수처: 창이엔지)를 이용하며, 혼합기를 사용할 경우는 침지 혼합 후 50~55℃에서 2시간동안 건조하였다. 코팅기를 사용할 경우는 코팅 조성물을 분사하여 건조하면서 코팅 건조하였다.As shown in Table 10 below, the white rice was coated in an amount of 200 g per 1 kg of white rice using the coating composition prepared by mixing the ginsujin mugwort extract and the starch solution obtained in Example 1 in a weight ratio of 5: 1. The coating is used a mixer (obtained by: RNL Life Sciences Co., Ltd.) or a coating machine (obtained by Changi Eng), and when the mixer is used, it is dried at 50-55 ° C. for 2 hours after immersion mixing. In the case of using a coating machine, the coating composition was sprayed and dried while the coating was dried.
제제예 5 내지 7Formulation Examples 5 to 7
하기 표 11에 나타낸 조성으로 하여 상기 제제예 1과 동일한 방법으로 코팅미를 제조하였다.To prepare a coating in the same manner as in Preparation Example 1 with the composition shown in Table 11.
시험예 4: 관능평가Test Example 4: Sensory Evaluation
10대 청소년 여성 10명, 남성 10명을 대상으로 일반미 및 코팅미의 관능평가를 수행하여, 그 결과를 하기 표 12에 나타내었다. 일반미를 5점으로 하여 일반미보다 우수할 시는 상위 10점까지 일반미보다 나쁠 시에는 하위 0점까지로 평가하였다.Sensory evaluation of the general beauty and the coating beauty were performed on 10 teenage adolescent females and 10 males, and the results are shown in Table 12 below. With 5 points for general beauty, the top 10 points were superior to the general beauty, and the lowest 0 points were worse than the general beauty.
상기 표 12에서 보듯이, 본 발명의 코팅미는 일반미보다 우수한 관능평가 결과를 나타내었다.As shown in Table 12, the coated rice of the present invention showed better sensory evaluation results than ordinary rice.
시험예 5 : 확산 방지 시험Test Example 5 Diffusion Prevention Test
상기 제제예 5 내지 7에서 제조된 코팅미를 밥솥에 넣고 가운데에 지름 10cm, 높이 4cm 정도의 구멍을 내고 코팅미를 넣은 후 취사하여 코팅액이 번지는 지를 관찰하였다. 코팅액은 다소 검은색을 띄고 있으므로, 색의 번짐으로 확산,비확산을 구별할 수 있다.The coated rice prepared in Formulation Examples 5 to 7 was put into a rice cooker, a hole having a diameter of 10 cm and a height of about 4 cm was placed in the center, and the coated rice was cooked to observe whether the coating liquid spreaded. Since the coating liquid is somewhat black, it is possible to distinguish diffusion and non-diffusion by color bleeding.
상기 표 13에서 보듯이, 본 발명에 따라 제조된 전분을 포함하는 코팅용 조성물을 이용하여 코팅된 코팅미는 취사시 코팅액의 확산이 방지됨을 알 수 있다.As shown in Table 13, it can be seen that the coating is coated using a coating composition comprising a starch prepared according to the present invention is prevented diffusion of the coating solution during cooking.
이와 같이, 인진쑥 추출물을 함유하는 본 발명의 조성물은 성장 촉진 또는 성장호르몬 분비 촉진 효과를 나타내므로, 이를 직접 약학 조성물로서 사용하거나 주식으로 이용되는 곡류에 코팅하기 위한 곡류 코팅용 조성물로 사용하여 우수한 성장 촉진 효과를 얻을 수 있으며, 본 발명에 따라 제조된 기능성 코팅 곡류는 성장 촉진효과를 나타낼 뿐 아니라 취사 시 코팅액의 확산이 일어나지 않고, 일반미와 비교하여 관능평가 결과도 우수하여 성장 촉진용 기능성 보조식품으로 널리 사용될 수 있다.As such, the composition of the present invention containing the extract of jinjinjin exhibits growth promoting or growth hormone secretion promoting effect, excellent growth by using it as a pharmaceutical composition or as a composition for grain coating for coating on cereals used as a stock The functional coating grains prepared according to the present invention can not only promote growth, but also do not cause diffusion of the coating liquid during cooking, and have excellent sensory evaluation results compared to general beauty products as functional supplements for growth promotion. It can be widely used.
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020020065230A KR100601265B1 (en) | 2002-10-24 | 2002-10-24 | A composition for promoting growth or secretion of growth hormone comprising an extract of artemisia capillaris thunberg. and functional cereals coated by same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020020065230A KR100601265B1 (en) | 2002-10-24 | 2002-10-24 | A composition for promoting growth or secretion of growth hormone comprising an extract of artemisia capillaris thunberg. and functional cereals coated by same |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20040036272A true KR20040036272A (en) | 2004-04-30 |
KR100601265B1 KR100601265B1 (en) | 2006-07-14 |
Family
ID=37334861
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020020065230A KR100601265B1 (en) | 2002-10-24 | 2002-10-24 | A composition for promoting growth or secretion of growth hormone comprising an extract of artemisia capillaris thunberg. and functional cereals coated by same |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100601265B1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006006768A1 (en) * | 2004-07-14 | 2006-01-19 | Rnl Life Science Ltd. | Composition for promoting growth of animal comprising extracts of artemisia capillaris thunberg, acanthopanax and garlic and feed composition for promoting growth comprising the composition |
KR101252630B1 (en) * | 2012-07-06 | 2013-04-09 | 우상하 | Useful composition for growth and development of children and youths |
CN116139227A (en) * | 2023-03-27 | 2023-05-23 | 李好臣 | Traditional Chinese medicine composition for clearing liver and increasing height and preparation method thereof |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101511365B1 (en) * | 2013-09-26 | 2015-04-10 | 김세원 | Method of preparing functional rice using lactic-acid bacteria and wild plants |
KR101822442B1 (en) | 2017-03-16 | 2018-01-26 | 박승찬 | Composition for prevention, improvement or treatment of precocious puberty comprising extracts of Coix lacryma-jobi L. var. ma-yuen Stapf seed and Artemisia capillaris Thunberg as an active ingredient |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11240823A (en) * | 1998-02-23 | 1999-09-07 | Shiseido Co Ltd | Activator for hair papilla |
KR100277193B1 (en) * | 1998-04-30 | 2001-01-15 | 마길자 | Health foods using motherwort or jinjin wormwood and its manufacturing method |
KR20000031764A (en) * | 1998-11-10 | 2000-06-05 | 전중자 | Wormwood noodle and process thereof |
KR20020030342A (en) * | 2000-10-17 | 2002-04-25 | 유해규 | Method for manufacturing health food made from carotene of INJIN mugwort |
KR100401472B1 (en) * | 2000-12-29 | 2003-10-10 | 한종현 | Functional beverage containing extract of Artermisia capillaris THUNB and process for preperation thereof |
KR20020025146A (en) * | 2002-02-27 | 2002-04-03 | 이종선 | Healthy foods with the theme of elm and Injin mugwort |
-
2002
- 2002-10-24 KR KR1020020065230A patent/KR100601265B1/en not_active IP Right Cessation
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006006768A1 (en) * | 2004-07-14 | 2006-01-19 | Rnl Life Science Ltd. | Composition for promoting growth of animal comprising extracts of artemisia capillaris thunberg, acanthopanax and garlic and feed composition for promoting growth comprising the composition |
KR101252630B1 (en) * | 2012-07-06 | 2013-04-09 | 우상하 | Useful composition for growth and development of children and youths |
CN116139227A (en) * | 2023-03-27 | 2023-05-23 | 李好臣 | Traditional Chinese medicine composition for clearing liver and increasing height and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
KR100601265B1 (en) | 2006-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101661793B1 (en) | Hyperlipemia-ameliorating agent, anemia-ameliorating composition, uric-acid-level-reducing composition, and foods and beverages | |
JP4937445B2 (en) | Bone metabolism improving agent and food for preventing or treating osteoporosis | |
KR20210122167A (en) | Composition for Preventing, Improving or Treating Postmenopausal Syndrome Comprising Rosa rugosa Thunberg Extract | |
JP2001122791A (en) | Meal enhancer comprising aqueous extract of red vine leaf for alleviation and prophylaxis of chronic venous insufficiency in lower extremity | |
KR101515915B1 (en) | Phytoestrogen Composition for Preventing or Alleviating Climacteric Syndrome and manufacturaring process for the same | |
JP4002654B2 (en) | Blood lipid improving agent, cyclic AMP phosphodiesterase inhibitor, obesity preventive / eliminating agent, food and beverage, and skin external preparation | |
KR100703180B1 (en) | A pharmaceutical composition comprising the extract of herb mixture for treating or preventing osteoporosis disease | |
KR101093009B1 (en) | Composition for preventing and relieving of menopausal symptoms comprising glyceollin | |
KR100601265B1 (en) | A composition for promoting growth or secretion of growth hormone comprising an extract of artemisia capillaris thunberg. and functional cereals coated by same | |
KR102080410B1 (en) | Composition for Preventing, Treating or Improving of Andropause Syndrome Comprising Elderberry Extracts | |
KR102087033B1 (en) | Compositions for reducing weight comprising Oenothera extract or its fraction as effective component | |
KR20030055127A (en) | Composition for anti-hyperlipidemia | |
KR20100129571A (en) | Functional composition for improvement of sex and food having the same | |
KR100727396B1 (en) | Composition comprising extract of Citrullus vulgaris bark and octacosanol | |
KR100686260B1 (en) | Composition comprising the extract from melandryum firmum for improvement of liver function and treatment of liver diseases | |
KR101821925B1 (en) | A composition comprising the complex extract of Poncirus trifoliata and Cinnamommum cassia for treating or preventing allergy desmatitis | |
Singh et al. | Lepidium sativum: Its nutritional composition and therapeutic properties | |
KR100718559B1 (en) | The functional food for menopausal symptoms and its composition | |
CN113456778A (en) | Composition for improving energy and preparation method thereof | |
KR101456127B1 (en) | A composition for increasing bone growth | |
KR100404455B1 (en) | Growth-promoting effects and pharmaceutical preparations containing the same | |
KR101966879B1 (en) | Composition for treating or preventing postmenopausal syndrome containing glycyrrizae radix extract, astragali radix extract and spatholobus suberectus extract | |
KR102070796B1 (en) | Composition for preventing, alleviating or treating ovarian dysfunction comprising extract of medicinal herb mixture as effective component | |
KR102652335B1 (en) | Composition for preventing and improving woman climacterium symptoms comprising Glycine soja seed | |
KR20170130082A (en) | A Composition Comprising the root extract of Achyranthes japonica NAKAI for preventing or improving the hormonal abnormal syndrome in women |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130702 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20140609 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20150703 Year of fee payment: 10 |
|
LAPS | Lapse due to unpaid annual fee |